Skip to content
Oncology Research Hub

Arkansas

Cancer clinical trials in Arkansas

122 cancer studies are recruiting participants at sites in 11 cities across Arkansas as of November 16, 2026, according to ClinicalTrials.gov.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Arkansas city with a recruiting study

By research area: Lung Cancer (41), Breast Cancer (29), Lymphoma (21), Prostate Cancer (15), Pancreatic Cancer (9), Melanoma (7).

Little Rock (60), Springdale (37), Jonesboro (27), Fayetteville (19), Fort Smith (16), Rogers (16), Hot Springs (11), North Little Rock (2), Bryant (1), Conway (1), Pine Bluff (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in Arkansas

Basic details from each study's public record (the 12 most recently updated of 122). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Jonesboro
    Registry record
    NCT05564377 · updated
  2. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Fort Smith · Jonesboro · Little Rock
    Registry record
    NCT06058377 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Arkansas on ClinicalTrials.gov.

Lung cancer: recently updated in Arkansas

  1. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Springdale
    Registry record
    NCT07063745 · updated
  2. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Jonesboro
    Registry record
    NCT04267848 · updated
  3. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Fayetteville · Fort Smith · Rogers · and 1 more U.S. location
    Registry record
    NCT06096844 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Arkansas on ClinicalTrials.gov.

Prostate cancer: recently updated in Arkansas

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Recruiting in
    Fort Smith
    Registry record
    NCT04423211 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Arkansas on ClinicalTrials.gov.

Melanoma: recently updated in Arkansas

  1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Little Rock
    Registry record
    NCT05136196 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Arkansas on ClinicalTrials.gov.

Lymphoma: recently updated in Arkansas

  1. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Hot Springs
    Registry record
    NCT06890884 · updated
  2. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Jonesboro
    Registry record
    NCT04269902 · updated
  3. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Little Rock
    Registry record
    NCT04546399 · updated
  4. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Little Rock
    Registry record
    NCT05675410 · updated
  5. TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

    • Phase 1/2
    • Up to age 1
    • All sexes
    Sponsor
    Tanja Andrea Gruber
    Recruiting in
    Little Rock
    Registry record
    NCT05848687 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Arkansas on ClinicalTrials.gov.

Ask about studies in Arkansas

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call